(Q43735458)

26 November 2017

title

Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke (English)

1 reference

26 November 2017

0 references

A G Turpie

1

1 reference

26 November 2017

M N Levine

2

1 reference

26 November 2017

J Hirsh

3

1 reference

26 November 2017

C J Carter

4

1 reference

26 November 2017

R M Jay

5

1 reference

26 November 2017

P J Powers

6

1 reference

26 November 2017

M Andrew

7

1 reference

26 November 2017

H N Magnani

8

1 reference

26 November 2017

R D Hull

9

1 reference

26 November 2017

M Gent

10

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 March 1987

1 reference

26 November 2017

1 reference

26 November 2017

volume

1

1 reference

26 November 2017

issue

8532

1 reference

26 November 2017

page(s)

523-526

1 reference

Venous thrombosis following strokes

26 November 2017

uses

randomized experiment

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2990173-5

7 January 2021

Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2990173-5

7 January 2021

Mortality Factors in Patients With Acute Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2990173-5

7 January 2021

Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2990173-5

7 January 2021

A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2990173-5

7 January 2021

Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2990173-5

7 January 2021

Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2990173-5

7 January 2021

Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2990173-5

7 January 2021

A novel anti-thrombotic heparinoid (ORG 10172) devoid of bleeding inducing capacity: A survey of its pharmacological properties in experimental animal models

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2990173-5

7 January 2021

Assay of heparin in plasma using a chromogenic substrate for activated factor X

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2990173-5

7 January 2021

The value of adding impedance plethysmography to 125I-fibrinogen leg scanning for the detection of deep vein thrombosis in high risk surgical patients: a comparative study between patients undergoing general surgery and hip surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2990173-5

7 January 2021

Roentgen diagnosis of venous thrombosis in the leg

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2990173-5

7 January 2021

Rationale behind the development of low molecular weight heparin derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2990173-5

7 January 2021

10.1016/S0140-6736(87)90173-5

Identifiers

DOI

1 reference

26 November 2017

1 reference